Within 24 hours of the release, community members began porting the algorithm to popular local AI libraries like MLX for Apple Silicon and llama.cpp.

Previous studies on stroke recurrence often ignored the competing risk of death, potentially biasing risk estimates. This study estimated stroke recurrence risk and identified associated factors among ...

Authors retain all rights in any data supplements associated with their articles The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of ...

MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), a technology service provider, released a core quantum machine learning technology oriented toward sequential learning tasks—the ...

Objective To undertake a contemporary review of the impact of exercise based cardiac rehabilitation (ExCR) for patients with atrial fibrillation (AF). Data sources CENTRAL, MEDLINE, Embase, PsycINFO, ...

ABSTRACT: Darcy’s law is the fundamental equation describing the flow of a fluid through a porous medium. Combined with the principle of mass conservation, it leads to the diffusion Equation (e.g., ...

aDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St Antonius Hospital Nieuwegein, Utrecht University, Utrecht, Netherlands bDepartment of Medical Oncology, ...

Abstract: This study investigates the effects of a 7-day Panchakarma therapy on cardiorespiratory coordination by applying Cross Recurrence Quantification Analysis (CRQA), a non-linear dynamical ...

Google has rolled out fewer confirmed search ranking updates in 2025, then it did in all the past years where Google confirmed these updates. Google rolled out only four confirmed updates in 2025, ...

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, ...